Evofem Biosciences (NASDAQ: EVFM)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-10 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -3.000 | -2.880 | 0.1200 | ||||
REV | 4.150M | 4.251M | 101.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Evofem Biosciences (NASDAQ: EVFM) through any online brokerage.
Other companies in Evofem Biosciences’s space includes: Cumberland (NASDAQ:CPIX), Iterum Therapeutics (NASDAQ:ITRM), Cocrystal Pharma (NASDAQ:COCP), Onconova Therapeutics (NASDAQ:ONTX) and Akanda (NASDAQ:AKAN).
The latest price target for Evofem Biosciences (NASDAQ: EVFM) was reported by Laidlaw & Co. on Thursday, June 2, 2022. The analyst firm set a price target for 3.50 expecting EVFM to rise to within 12 months (a possible 209.73% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Evofem Biosciences (NASDAQ: EVFM) is $1.13 last updated June 30, 2022, 8:00 PM UTC.
There are no upcoming dividends for Evofem Biosciences.
Evofem Biosciences’s Q2 earnings are confirmed for Wednesday, August 10, 2022.
There is no upcoming split for Evofem Biosciences.
Evofem Biosciences is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.